Pemvidutide
vs Survodutide.
Compare pemvidutide and survodutide by GLP-1/glucagon mechanism, obesity and MASH trials, weight results, tolerability, Phase 3 status, and approval limits.
What is the difference?
Pemvidutide and survodutide are separate investigational once-weekly GLP-1/glucagon dual agonists with no head-to-head trial. Pemvidutide has a completed Phase 2 obesity study, a completed Phase 2b MASH study, and a planned MASH Phase 3 program. Survodutide has an active Phase 3 program with reported 76-week obesity results and liver-focused studies. Neither is approved for marketing. Their receptor labels overlap, but the molecules, development priorities, doses, populations, durations, efficacy analyses, and gastrointestinal discontinuation records differ, so they are not interchangeable and the available percentages cannot name a winner.
See the useful differences first.
Start with identity, current US status, trial coverage, and the evidence relationship. Then carry the exact pair into a country-aware workspace without losing either record.
Pemvidutide
Investigational - not FDA approved
- Route
- Once-weekly subcutaneous injection
- Registry
- 9 matched NCT records
- Sponsor
- Altimmune
Survodutide
Investigational - not approved for marketing
- Route
- Once-weekly subcutaneous injection
- Registry
- 31 matched NCT records
- Sponsor
- Boehringer Ingelheim + Zealand Pharma
Pemvidutide vs Survodutide: how direct is the evidence?
No participant in the cited sources was randomized between Pemvidutide and Survodutide. Identity, mechanism, route, trial design, and regulatory status can be compared. Subtracting percentages from separate studies would create a treatment effect the evidence did not test.
Pemvidutide
Balanced 1:1 GLP-1 and glucagon receptor dual agonist
- Route
- Once-weekly subcutaneous injection
- Stage
- Phase 2 programs active; MASH Phase 3 planned
- Status
- Investigational - not FDA approved
Two evidence records, no shared randomization.
Treat percentages as separate source records. Do not subtract them, divide them into weekly rates, or use the larger value to name a winner.
No randomized head-to-head trialSurvodutide
Glucagon + GLP-1 receptor dual agonist
- Route
- Once-weekly subcutaneous injection
- Stage
- Phase 3 program active and reporting
- Status
- Investigational - not approved for marketing
The current exact-intervention dataset contains 268 unique NCT records across 13 tracked investigational programs. Counts describe registry coverage, not comparative evidence strength.
matched NCT records
- Recruiting
- 1
- Results posted
- 0
- Recruiting site observations
- 8
matched NCT records
- Recruiting
- 3
- Results posted
- 3
- Recruiting site observations
- 774
Compare the named molecules, active components, sponsors, and receptor strategies.
Compare the studied route, frequency, development phase, and exact program record.
Compare exact approvals, applications, and investigational status in the jurisdiction being checked.
Treat percentages as separate source records. Do not subtract them, divide them into weekly rates, or use the larger value to name a winner.
Use only adverse-event evidence reported for the cited protocol. Separate studies cannot establish which program is safer.
No group result, receptor count, route, approval milestone, or chart position predicts the best choice for one person.
Check both programs in the same market.
Approval, trial activity, product registration, pharmacy rules, and seller authority are country specific. Open both records before treating a status from one market as valid in another.
Pemvidutide
Balanced 1:1 GLP-1 and glucagon receptor dual agonist
- Route
- Once-weekly subcutaneous injection
- Stage
- Phase 2 programs active; MASH Phase 3 planned
- Status
- Investigational - not FDA approved
- Featured trial anchors
- NCT05989711 · NCT06987513 · NCT07009860 · NCT05006885
Survodutide
Glucagon + GLP-1 receptor dual agonist
- Route
- Once-weekly subcutaneous injection
- Stage
- Phase 3 program active and reporting
- Status
- Investigational - not approved for marketing
- Featured trial anchors
- NCT06066515 · NCT06066528 · NCT06077864 · NCT06309992
Compare the field, then read the limit.
This is the closest target-level comparison for pemvidutide because both programs combine GLP-1 and glucagon receptor activity and emphasize liver as well as weight outcomes. That similarity makes it especially important to preserve the distinctions. Pemvidutide's current sponsor focus is MASH and alcohol-related liver conditions, while survodutide has a broad Phase 3 obesity, cardiovascular, and liver program. Matching target labels do not create matching clinical evidence.
| Field | Pemvidutide | Survodutide | How to interpret it |
|---|---|---|---|
| Core mechanism | Balanced 1:1 GLP-1 and glucagon receptor dual agonist | Glucagon and GLP-1 receptor dual agonist | Shared receptor names do not make molecular balance, pharmacology, dose, efficacy, or tolerability equivalent. |
| Obesity evidence | 15.6% mean change at 48 weeks in Phase 2 MOMENTUM | Up to 16.6% at 76 weeks under a Phase 3 efficacy estimand | Phase, duration, estimand, dose strategy, and study population differ, so the percentages cannot establish comparative effectiveness. |
| Liver program | Completed IMPACT MASH Phase 2b; PERFORMA MASH Phase 3 planned | Phase 3 liver, obesity, and cardiometabolic development program active | Disease-specific histology, imaging, fibrosis, and weight endpoints should remain attached to the trial that measured them. |
| Tolerability context | About 1% adverse-event discontinuation reported in IMPACT's MASH population | 19.0% gastrointestinal-event discontinuation reported in SYNCHRONIZE-1 | These rates come from different populations and protocols and cannot be compared as a direct safety estimate. |
| Current status | Investigational and not FDA approved | Investigational and not approved for marketing | Trial progress and FDA designations do not create an approved dose, pharmacy product, price, coverage policy, or supply route. |
Why the headline numbers do not name a winner.
MOMENTUM reported 15.6% mean loss with pemvidutide 2.4 mg at 48 weeks versus 2.2% with placebo in a Phase 2 obesity population. SYNCHRONIZE-1 reported up to 16.6% average loss with survodutide at 76 weeks under an efficacy estimand versus 3.2% with placebo in Phase 3. IMPACT and survodutide's liver studies answer additional disease-specific questions. No participant was randomized between the molecules, and dose, phase, population, duration, estimand, discontinuation, and missing-data methods prevent a fair numerical ranking.
Keep the comparison honest.
- 01
Keep obesity, MASH, liver-fat, fibrosis, and cardiometabolic endpoints attached to their own protocols rather than merging them into one score.
- 02
Do not compare the 48-week Phase 2 and 76-week Phase 3 weight figures without their estimands, populations, doses, placebo responses, and discontinuations.
- 03
Treat both names as investigational programs and reject any claim that a same-name online vial inherits sponsor evidence, regulatory status, or authenticity.
A country-specific approval, clinical trial, or matching name does not authenticate an online product or establish access elsewhere. This page contains no treatment recommendation, buying route, personal-use protocol, or affiliate link.
Open the safety and status guide →